Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 83673-98-7 | MDL No. : | MFCD02181057 |
Formula : | C9H12N2O4S | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | PIWSRJPUYPNQJE-UHFFFAOYSA-N |
M.W : | 244.27 | Pubchem ID : | 1502051 |
Synonyms : |
|
Num. heavy atoms : | 16 |
Num. arom. heavy atoms : | 5 |
Fraction Csp3 : | 0.44 |
Num. rotatable bonds : | 5 |
Num. H-bond acceptors : | 5.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 59.32 |
TPSA : | 116.76 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.58 cm/s |
Log Po/w (iLOGP) : | 1.59 |
Log Po/w (XLOGP3) : | 1.71 |
Log Po/w (WLOGP) : | 2.0 |
Log Po/w (MLOGP) : | 0.33 |
Log Po/w (SILICOS-IT) : | 1.27 |
Consensus Log Po/w : | 1.38 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.56 |
Log S (ESOL) : | -2.33 |
Solubility : | 1.13 mg/ml ; 0.00465 mol/l |
Class : | Soluble |
Log S (Ali) : | -3.78 |
Solubility : | 0.0408 mg/ml ; 0.000167 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -1.63 |
Solubility : | 5.78 mg/ml ; 0.0237 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 3.01 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H332-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
100% | With water; potassium hydroxide In tetrahydrofuran at 20℃; for 2 h; | General procedure: An aqueous KOH (10percent w/v) solution was added to an ester solution in THF. The reaction mixture was stirred at room temperature until reagent disappearance was confirmed by TLC. HCl 1 M was added until pH 4 and the solution was extracted with EtOAc.The organic layer was dried over MgSO4 and concentrated in vacuoto afford the acid. |
94% | Stage #1: With lithium hydroxide In tetrahydrofuran; water Stage #2: With hydrogenchloride In tetrahydrofuran; water |
(2) Lithium hydroxide monohydrate (20.16 g, 0.48 mol) was added to a stirred solution of 2-tert-butoxycarbonylamino-thiazole-4-carboxylic acid ethyl ester (52.35 g, 0.192 mol) in a mixture of tetrahydrofuran (800 mL) and water (200 mL). The mixture was stirred over night. 1 N Aqueous hydrochloric acid (480 mL) was added and the reaction mixture concentrated in vacuo to remove tetrahydrofuran. The mixture was then diluted with water and filtered. The solid was washed with water, ether and dried overnight to give 2-tert-butoxycarbonylamino-thiazole-4-carboxylic acid (43.9 g, 94percent). |
80.5% | With water; sodium hydroxide In tetrahydrofuran; methanol at 20℃; for 3 h; | A mixture of compound 2 (11.5 g, 42.3mmol), NaOH (3.4 g, 84.6 mol) and H2O (5 ml) in a mixture solvent of CH3OH (40 ml) and THF (40 ml), was stirred at room temperature for 3h. The solvent was evaporated in vacuo, the residue was dissolved with ethyl acetate (40 ml) and H2O (10ml), the separated aqueous layer was acidized with HCl (12 mol/L) to get white precipitate. The mixture was filtered and the filtered cake was washed with a small amount of H2O, dried in vacuo to give compound 3 as a white solid (8.3 g, yield 80.5percent). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
76% | With water; lithium hydroxide In tetrahydrofuran at 20℃; for 12 h; | To a solution of methyl 2-[[(tert-butoxy)carbonyl]amino]-l,3-thiazole-4-carboxylate (28 g, 108 mmol) in tetrahydrofuran (300 mL) was added a solution of lithium hydroxide (10.4 g, 433 mmol) in water (150 mL). The resulting mixture was stirred for 12 h at room temperature. The pH of the solution was adjusted to 4 with hydrochloric acid (2 mol/L). The solids were collected by filtration to afford 2- [[(teri-butoxy)carbonyl]amino]-l,3-thiazole-4-carboxylic acid (20 g, 76percent) as an off-white solid. LCMS (ESI): M+H+ = 245.0. |
71% | Stage #1: With lithium hydroxide In tetrahydrofuran; water at 20℃; Stage #2: With hydrogenchloride In water |
2-tert-Butoxycarbonylamino-thiazole-4-carboxylic acid methyl ester (15.5 g, 60.01 mmol) was dissolved in 4:1 tetrahydrofuran:water (300 mL) followed by the addition of lithium hydroxide monohydrate (5.29 g, 126.07 mmol). The solution was stirred overnight at room temperature. Tetrahydrofuran was removed under vacuum and the salt was neutralized with 2.0 N aqueous hydrochloric acid. The resulting precipitate was filtered and dried to give 2-tert-butoxycarbonylamino-thiazole-4-carboxylic acid (10.4 g, 71percent). |
[ 494769-44-7 ]
tert-Butyl (4-(hydroxymethyl)thiazol-2-yl)carbamate
Similarity: 0.91
[ 914349-71-6 ]
Methyl 5-bromo-2-((tert-butoxycarbonyl)amino)thiazole-4-carboxylate
Similarity: 0.85
[ 668484-45-5 ]
2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)thiazole-4-carboxylic acid
Similarity: 0.84
[ 1001419-35-7 ]
tert-Butyl (4-(bromomethyl)thiazol-2-yl)carbamate
Similarity: 0.80
[ 867065-53-0 ]
Ethyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)thiazole-4-carboxylate
Similarity: 0.80
[ 494769-44-7 ]
tert-Butyl (4-(hydroxymethyl)thiazol-2-yl)carbamate
Similarity: 0.91
[ 914349-71-6 ]
Methyl 5-bromo-2-((tert-butoxycarbonyl)amino)thiazole-4-carboxylate
Similarity: 0.85
[ 1001419-35-7 ]
tert-Butyl (4-(bromomethyl)thiazol-2-yl)carbamate
Similarity: 0.80
[ 170961-15-6 ]
tert-Butyl thiazol-2-ylcarbamate
Similarity: 0.76
[ 668484-45-5 ]
2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)thiazole-4-carboxylic acid
Similarity: 0.84
[ 86978-24-7 ]
(Z)-2-(2-((tert-Butoxycarbonyl)amino)thiazol-4-yl)pent-2-enoic acid
Similarity: 0.73
[ 302964-02-9 ]
2-Boc-Aminothiazole-5-carboxylic acid
Similarity: 0.71
[ 952182-68-2 ]
2-(Piperidin-1-yl)thiazole-4-carboxylic acid
Similarity: 0.69
[ 115065-79-7 ]
2-(2-(((Benzyloxy)carbonyl)amino)thiazol-4-yl)-5-((3-methylbut-2-en-1-yl)oxy)-5-oxopent-2-enoic acid
Similarity: 0.68
[ 494769-44-7 ]
tert-Butyl (4-(hydroxymethyl)thiazol-2-yl)carbamate
Similarity: 0.91
[ 914349-71-6 ]
Methyl 5-bromo-2-((tert-butoxycarbonyl)amino)thiazole-4-carboxylate
Similarity: 0.85
[ 668484-45-5 ]
2-(4-(tert-Butoxycarbonyl)piperazin-1-yl)thiazole-4-carboxylic acid
Similarity: 0.84
[ 1001419-35-7 ]
tert-Butyl (4-(bromomethyl)thiazol-2-yl)carbamate
Similarity: 0.80
[ 867065-53-0 ]
Ethyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)thiazole-4-carboxylate
Similarity: 0.80